Treatment of Acne in Pregnancy

References

1. 1.↵
   1. Akhavan A,
   2. Bershad S

   . Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003;4:473–92.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Jones SV,
   2. Ambros-Rudolph C,
   3. Nelson-Piercy C

   . Skin disease in pregnancy. BMJ 2014;348:g3489.

   OpenUrlFREE Full Text
3. 3.↵
   1. Pugashetti R,
   2. Shinkai K

   . Treatment of acne vulgaris in pregnant patients. Dermatol Ther 2013;26:302–11.

   OpenUrlPubMed
4. 4.↵
   1. Dréno B,
   2. Blouin E,
   3. Moyse D,
   4. Bodokh I,
   5. Knol A,
   6. Khammari A

   . Acne in pregnant women: a French survey. Acta Derm Venereol 2014;94:82–3.

   OpenUrlPubMed
5. 5.↵
   1. Wolverton SE

   , ed. Comprehensive dermatologic drug therapy. 3rd ed. Philadelphia: Saunders; 2012.
6. 6.↵
   1. Murase JE,
   2. Heller MM,
   3. Butler DC

   . Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad Dermatol 2014;70:401.e1–14; quiz 415.

   OpenUrl
7. 7.↵
   1. Williams HC,
   2. Dellavalle RP,
   3. Garner S

   . Acne vulgaris. Lancet 2012;379:361–72.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Parry MF,
   2. Rha CK

   . Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986;122:583–4.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Siegle RJ,
   2. Fekety R,
   3. Sarbone PD,
   4. Finch RN,
   5. Deery HG,
   6. Voorhees JJ

   . Effects of topical clindamycin on intestinal microflora in patients with acne. J Am Acad Dermatol 1986;15(2 Pt 1):180–5.

   OpenUrlPubMedWeb of Science
10. 10.↵
    1. Patel M,
    2. Bowe WP,
    3. Heughebaert C,
    4. Shalita AR

    . The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010;9:655–64.

    OpenUrlPubMedWeb of Science
11. 11.↵
    1. Kinney MA,
    2. Yentzer BA,
    3. Fleischer AB,
    4. Feldman SR

    . Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? J Drugs Dermatol 2010;9:519–24.

    OpenUrlPubMed
12. 12.↵
    1. Berard A,
    2. Azoulay L,
    3. Koren G,
    4. Blais L,
    5. Perreault S,
    6. Oraichi D

    . Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007;63:196–205.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Panchaud A,
    2. Csajka C,
    3. Merlob P

    . Pregnancy outcome following exposure to topical retinoids: prospective study. J Clin Pharmacol 2012;52:1844–51.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Kaplan YC,
    2. Ozsarfati J,
    3. Etwel F,
    4. Nickel C,
    5. Nulman I,
    6. Koren G

    . Pregnancy outcomes following first trimester exposure to topical retinoids : a systematic review and meta-analysis. Br J Dermatol 2015;173:1132–41.

    OpenUrlPubMed
15. 15.↵
    1. Gamble R,
    2. Dunn J,
    3. Dawson A,
    4. et al

    . Topical antimicrobial treatment of acne vulgaris: an evidence-based review. Am J Clin Dermatol 2012;13:141–52.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Nosten F,
    2. McGready R,
    3. d'Alessandro U,
    4. et al

    . Antimalarial drugs in pregnancy: a review. Curr Drug Saf 2006;1:1–15.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. James KA,
    2. Burkhart CN,
    3. Morrell DS

    . Emerging drugs for acne. Expert Opin Emerg Drugs 2009;14:649–59.

    OpenUrlPubMed
18. 18.↵
    1. Kong YL,
    2. Tey HL

    . Treatment of acne vulgaris during pregnancy and lactation. Drugs 2013;73:779–87.

    OpenUrlPubMed
19. 19.↵
    1. Thiboutot D,
    2. Gollnick H,
    3. Bettoli V,
    4. et al

    . New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol 2009;60(5 Suppl):S1–50.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Romoren M,
    2. Lindbaek M,
    3. Nordeng H

    . Pregnancy outcome after gestational exposure to erythromycin-a population-based register study from Norway. Br J Clin Pharmacol 2012;74:1053–62.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Al Hammadi A,
    2. Al-Haddab M,
    3. Sasseville D

    . Dermatologic treatment during pregnancy: practical overview. J Cutan Med Surg 2006;10:183–92.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Hale EK,
    2. Pomeranz MK

    . Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol 2002;41:197–203.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Lin KJ,
    2. Mitchell AA,
    3. Yau W-P,
    4. Louik C,
    5. Hernández-Díaz S

    . Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology 2012;23:699–705.

    OpenUrlPubMed
24. 24.↵
    1. Turowski CB,
    2. James WD

    . The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. Adv Dermatol 2007;23:155–63.

    OpenUrlPubMed
25. 25.↵
    1. Fenner JA,
    2. Wiss K,
    3. Levin NA

    . Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol 2008;25:179–83.

    OpenUrlPubMed
26. 26.↵
    1. Andersen JT,
    2. Petersen M,
    3. Jimenez-Solem E,
    4. et al

    . Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study. Epidemiol Infect 2013;141:1749–55.

    OpenUrl
27. 27.↵
    1. Park-Wyllie L,
    2. Mazzotta P,
    3. Pastuszak A,
    4. et al

    . Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385–92.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Rennick GJ

    . Use of systemic glucocorticosteroids in pregnancy: be alert but not alarmed. Australas J Dermatol 2006;47:34–6.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Gur C,
    2. Diav-Citrin O,
    3. Shechtman S,
    4. Arnon J,
    5. Ornoy A

    . Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004;18:93–101.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Dréno B,
    2. Blouin E

    . [Acne, pregnant women and zinc salts: a literature review]. Ann Dermatol Venereol 2008;135:27–33.

    OpenUrlPubMed
31. 31.↵
    1. Brocard A,
    2. Dréno B

    . Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol 2011;25:1146–52.

    OpenUrlPubMed
32. 32.↵
    1. Brandt S

    . The clinical effects of zinc as a topical or oral agent on the clinical response and pathophysiologic mechanisms of acne: a systematic review of the literature. J Drugs Dermatol 2013;12:542–5.

    OpenUrlPubMed
33. 33.↵
    1. Taub AF

    . Procedural treatments for acne vulgaris. Dermatol Surg 2007;33:1005–26.

    OpenUrlPubMed
34. 34.↵
    1. Hongcharu W,
    2. Taylor CR,
    3. Chang Y,
    4. Aghassi D,
    5. Suthamjariya K,
    6. Anderson RR

    . Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000;115:183–92.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. de Leeuw J,
    2. van der Beek N,
    3. Bjerring P,
    4. Neumann HAM

    . Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol 2010;24:460–9.

    OpenUrlPubMed
36. 36.
    1. Dréno B,
    2. Layton A,
    3. Zouboulis CC,
    4. et al

    . Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol 2013;27:1063–70.

    OpenUrlPubMed
37. 37.
    1. Purdy S,
    2. de Berker D

    . Acne vulgaris. BMJ Clin Evid 2011;2011. pii. 1714.